Biotechnology Assets, S.A (BST) Fair Value & Analysis
Healthcare · ES · Market cap €18.6M
Fair value as of: Jun 24, 2026
From 6 valuation models · updated 5 days ago
Share price −6.4% over the past month.
Price vs Fair Value (12 months)
12‑month range €0.1879 – €0.4727 · fair‑value band €0.2800 – €0.4700 · the €0.2420 price screens below the €0.3700 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Biotechnology Assets, S.A (BST) currently trades at €0.2420, while our model-based Fair Value estimate is €0.3700 — implying the stock looks roughly 52.9% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Biotechnology Assets, S.A generated revenue of €3.1M at a net margin of -68.1%. Revenue grew 8.0% year over year. It earns a return on equity of -30.4%. Net debt stands at €1.3M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VACC-ZERA technology, a tool to generate recombinant proteins in microparticles suited for therapeutic and prophylactic adjuvant free vaccines administered as DNA vaccines; and CLICK'N CUT, a tool to obtain tag-less proteins in a one-step process based on intein affinity, as well as Zebrafish assays. The company is based in Cádiz, Spain.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Biotechnology Assets, S.A reported revenue of €3.1M in FY2025 versus €3.1M in FY2021, a compound +0.0%/yr. Reported net income was −€1.9M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Biotechnology Assets, S.A (BST) undervalued?
What is the fair value of BST?
What is the quality score of BST?
What is the revenue of Biotechnology Assets, S.A (BST)?
What is the net profit margin of BST?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.